Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

3.8%

5 terminated/withdrawn out of 132 trials

Success Rate

95.7%

+9.2% vs industry average

Late-Stage Pipeline

31%

41 trials in Phase 3/4

Results Transparency

47%

52 of 111 completed trials have results

Key Signals

8 recruiting52 with results

Enrollment Performance

Analytics

Phase 1
52(40.6%)
Phase 3
37(28.9%)
Phase 2
33(25.8%)
Phase 4
4(3.1%)
N/A
2(1.6%)
128Total
Phase 1(52)
Phase 3(37)
Phase 2(33)
Phase 4(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (132)

Showing 20 of 132 trials
NCT05953480Phase 2Active Not Recruiting

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Role: lead

NCT07214571Phase 2Recruiting

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Role: lead

NCT06776432Phase 2Active Not Recruiting

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

Role: lead

NCT07123155Phase 2Recruiting

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

Role: lead

NCT05588323Phase 1Recruiting

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

Role: lead

NCT05101070Phase 1Recruiting

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Role: lead

NCT06086626Phase 2Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Role: lead

NCT07018492Phase 1Completed

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

Role: lead

NCT04335539Phase 2Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Role: lead

NCT07012005Phase 1Completed

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

Role: lead

NCT06717438Phase 2Active Not Recruiting

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

Role: lead

NCT05101187Phase 3Active Not Recruiting

Olorofim Aspergillus Infection Study

Role: collaborator

NCT05212948Phase 3Completed

A Study of S-268019 for the Prevention of COVID-19

Role: lead

NCT07217886Phase 1Recruiting

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

Role: lead

NCT06724978Phase 1Completed

A Study of S-740792 in Healthy Adult Study Participants

Role: lead

NCT06928051Phase 2Completed

A Study of S-892216 in Participants With COVID-19

Role: lead

NCT05305547Phase 3Completed

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

Role: lead

NCT07093580Phase 1Recruiting

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

Role: lead

NCT07011992Phase 1Completed

A Study to Assess the Effects of BPN14770 on Rosuvastatin

Role: lead

NCT05897541Phase 3Completed

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Role: lead